- 14 Mar 2002
- 15,973
- 9,214
- 749
- Thread starter
- #851
In other related news:
Yesterday, Japan saw more than 22,000 new cases of infections, 4,051 in Tokyo alone.
The quarantine period for international arrivals has been shortened to 10 days, as has the interval for COVID boosters (7 months) as well as the isolation period for close contacts.
Pfizer Japan has applied for approval of its COVID-19 pill which would make it the second oral drug for mild coronavirus cases available.
Yesterday, Japan saw more than 22,000 new cases of infections, 4,051 in Tokyo alone.
The quarantine period for international arrivals has been shortened to 10 days, as has the interval for COVID boosters (7 months) as well as the isolation period for close contacts.
Pfizer Japan has applied for approval of its COVID-19 pill which would make it the second oral drug for mild coronavirus cases available.
The Ministry of Health Labor and Welfare has already approved the oral drug molnupiravir, developed by U.S. pharmaceutical company Merck & Co in December. Health minister Shigeyuki Goto said in December that oral drugs are expected to play a significant role in treating sufferers of mild COVID-19 symptoms. Clinical trials have shown that Paxlovid has a higher chance of preventing hospitalizations and deaths compared to molnupiravir, cutting such risks by 88 percent for patients who took the drug within five days of the onset of symptoms, compared to those who were given a placebo, according to the company The pill, which prevents the coronavirus from multiplying in the body, is prescribed to be taken twice a day for five days.
Pfizer seeks approval for oral COVID-19 pill in Japan
Pfizer Japan Inc said Friday it has applied to the Japanese health ministry for approval of its COVID-19 pill which, if granted, would make it the second oral drug for mild coronavirus cases available in the country. The new drug application for Paxlovid, a combination of two antiviral drugs...
japantoday.com